Aroa Biosurgery (ASX:ARX) FCF Margin %: 7.53% (As of Mar. 2026)


ASX:ARX Aroa Biosurgery Ltd ASX:ARX
62 GF Score
Price A$0.59
GF Value A$0.80
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Aroa Biosurgery FCF Margin %?

Aroa Biosurgery ASX:ARX +0.85% 62 FCF Margin % is 7.53% as of Mar. 2026. GuruFocus rates ASX:ARX with a GF Score™ of 62/100 and a GF Value™ of A$0.80 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 815 Medical Devices & Instruments companies, Aroa Biosurgery ranks better than 65.89% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Aroa Biosurgery's Free Cash Flow for the six months ended in Mar. 2026 was A$3.58 Mil. Aroa Biosurgery's Revenue for the six months ended in Mar. 2026 was A$47.49 Mil. Therefore, Aroa Biosurgery's FCF Margin % for the quarter that ended in Mar. 2026 was 7.53%.

As of today, Aroa Biosurgery's current FCF Yield % is 2.78%.

The historical rank and industry rank for Aroa Biosurgery's FCF Margin % or its related term are showing as below:

ASX:ARX' s FCF Margin % Range Over the Past 10 Years
Min: -41.31   Med: -19.38   Max: 6.56
Current: 6.56

During the past 7 years, the highest FCF Margin % of Aroa Biosurgery was 6.56%. The lowest was -41.31%. And the median was -19.38%.

ASX:ARX's FCF Margin % is ranked better than
65.89% of 815 companies
in the Medical Devices & Instruments industry
Industry Median: -0.03 vs ASX:ARX: 6.56

Aroa Biosurgery FCF Margin % Related Terms

Aroa Biosurgery FCF Margin % Historical Data

* Premium members only.

The historical data trend for Aroa Biosurgery's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aroa Biosurgery FCF Margin % Chart

Aroa Biosurgery Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
FCF Margin %
Get a 7-Day Free Trial -41.31 -17.97 -20.79 -7.40 6.56

Aroa Biosurgery Semi-Annual Data
Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.94 -18.06 1.93 5.39 7.53

ASX:ARX vs ABT, SYK, MDT: FCF Margin % Comparison

For the Medical Devices subindustry, Aroa Biosurgery's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aroa Biosurgery FCF Margin % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aroa Biosurgery's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Aroa Biosurgery's FCF Margin % falls into.


ASX:ARX
62GF Score
Aroa Biosurgery Ltd ASX:ARX
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aroa Biosurgery FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Aroa Biosurgery's FCF Margin for the fiscal year that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (A: Mar. 2026 )/Revenue (A: Mar. 2026 )
=5.683/86.603
=6.56 %

Aroa Biosurgery's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=3.575/47.488
=7.53 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of 7.53% mean?
Aroa Biosurgery (ASX:ARX) has a FCF Margin % of 7.53% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aroa Biosurgery and its competitors. According to the industry distribution chart, Aroa Biosurgery ranks #278 out of 815 companies in the Medical Devices & Instruments industry, placing it in the top 34.1%.
Is Aroa Biosurgery's FCF Margin % too high?
Aroa Biosurgery's current FCF Margin % is 7.53%. Based on the distribution chart, Aroa Biosurgery ranks #278 out of 815 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Aroa Biosurgery has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aroa Biosurgery's FCF Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Aroa Biosurgery ranks #278 out of 815 companies for FCF Margin %. This puts Aroa Biosurgery in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Devices & Instruments company?
A good FCF Margin % depends on the Medical Devices & Instruments industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Aroa Biosurgery and its competitors. Aroa Biosurgery's current FCF Margin % is 7.53%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aroa Biosurgery stock overvalued right now?
Based on GuruFocus' analysis, Aroa Biosurgery (ASX:ARX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$0.80, compared to a current price of A$0.59 — trading 26.3% below its estimated fair value. The current FCF Margin % is 7.53%. Aroa Biosurgery's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Aroa Biosurgery (ASX:ARX), the current FCF Margin % is 7.53% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aroa Biosurgery (ASX:ARX) Overvalued in 2026?

Based on GuruFocus' analysis, Aroa Biosurgery stock appears to be undervalued. The current stock price of A$0.59 is trading 26.3% below its estimated GF Value™ of A$0.80. GuruFocus considers Aroa Biosurgery to be Modestly Undervalued.

Key valuation signals for ASX:ARX:

  • FCF Margin %: 7.53%
  • GF Value™: A$0.80 vs. price of A$0.59 (26.3% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the ASX:ARX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aroa Biosurgery Business Description

Other Exchanges AROAF:USA
Address 64 Richard Pearse Drive, Mangere, Airport Oaks, Auckland, NZL, 2022
Aroa Biosurgery Ltd is a soft tissue regeneration company that develops, manufactures, and sells medical devices for wound and soft tissue repair using its proprietary extracellular matrix (ECM) technology. It is focused on improving the rate and quality of healing in complex wounds and soft tissue reconstruction. The company is in the business of developing, manufacturing, and selling soft tissue repair products. The company's principal market is the United States, where it has five key products for sale targeting chronic wounds, hernia, plastics, reconstructive surgery, and trauma/limb salvage/tumor surgery.
62GF Score

Get the complete analysis for ASX:ARX

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.59
Price
A$0.80
GF Value